{
  "keyword": [
    "JCAR017",
    "lisocabtagene maraleucel",
    "NHL",
    "chimeric antigen receptor",
    "CAR",
    "CAR T cell",
    "autologous T cell therapy",
    "immunotherapy",
    "cell therapy",
    "liso-cel"
  ],
  "condition": [
    "Lymphoma, Non-Hodgkin",
    "Lymphoma, Nonhodgkin",
    "Lymphoma, B-Cell",
    "Lymphoma, Large B-Cell, Diffuse"
  ],
  "primary_outcome": [
    {
      "measure": "Antitumor activity",
      "time_frame": "Through Month 24",
      "description": "Overall response rate (complete response + partial response) based on  Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification "
    }
  ],
  "secondary_outcome": [
    {
      "measure": "Adverse events",
      "time_frame": "90 days",
      "description": "Proportion of subjects experiencing adverse events"
    },
    {
      "measure": "Laboratory abnormalities",
      "time_frame": "90 days",
      "description": "Proportion of subjects experiencing laboratory abnormalities"
    },
    {
      "measure": "Antitumor activity",
      "time_frame": "Through Month 24",
      "description": "Complete response rate based on  Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification "
    },
    {
      "measure": "Antitumor activity",
      "time_frame": "Through Month 24",
      "description": "Duration of response"
    },
    {
      "measure": "Maximum concentration (Cmax) of lisocabtagene maraleucel in blood",
      "time_frame": "Through Month 24",
      "description": "Maximum concentration of lisocabtagene maraleucel in blood"
    },
    {
      "measure": "Time of the maximum concentration (Tmax) of lisocabtagene maraleucel in blood",
      "time_frame": "Through Month 24",
      "description": "Time of the maximum concentration of lisocabtagene maraleucel in blood"
    },
    {
      "measure": "Area under the curve of (AUC) lisocabtagene maraleucel concentration in blood",
      "time_frame": "Through Month 24",
      "description": "Area under the curve of lisocabtagene maraleucel in blood"
    },
    {
      "measure": "Progression-free survival",
      "time_frame": "Through Month 24",
      "description": "Progression-free survival"
    },
    {
      "measure": "Overall survival",
      "time_frame": "Through Month 24",
      "description": "Overall survival"
    },
    {
      "measure": "Health-related quality of life and health economics and outcomes research",
      "time_frame": "Through Month 24",
      "description": "The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 is a validated quality of life measure applicable to subjects with any cancer diagnosis. It is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms. A 10 point change in the scoring is considered to be a meaningful change in HRQoL."
    },
    {
      "measure": "Health-related quality of life and health economics and outcomes research",
      "time_frame": "Through Month 24",
      "description": "The EuroQol-5D (EQ-5D) is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS). The descriptive system comprises dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). The VAS rating scale is a vertical 20 cm visual analogue scale with the end points labeled best imaginable health state at the top and worst imaginable health state at the bottom having numeric values of 100 and 0 respectively. The participant is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions."
    },
    {
      "measure": "Health-related quality of life and health economics and outcomes research",
      "time_frame": "Through Month 24",
      "description": "Numbers of intensive care unit inpatient days and non-ICU inpatient days and reasons for hospitalization"
    }
  ],
  "other_outcome": [],
  "reference": [],
  "results_reference": [],
  "link": [],
  "location": [
    {
      "facility": {
        "name": "University of Pittsburgh Medical Center, Hillman Cancer Center",
        "address": {
          "city": "Pittsburgh",
          "state": "Pennsylvania",
          "zip": "15232",
          "country": "United States"
        }
      },
      "status": "Not yet recruiting",
      "contact": {
        "first_name": "",
        "middle_name": "",
        "last_name": "Linda Fukas, RN",
        "degrees": "",
        "phone": "412-623-6037",
        "phone_ext": "",
        "email": "fukaslj@upmc.edu"
      },
      "contact_backup": {
        "first_name": "",
        "middle_name": "",
        "last_name": "Bridget Sweterlitsch",
        "degrees": "",
        "phone": "",
        "phone_ext": "",
        "email": "sweterlitschbm@ph.upmc.edu"
      },
      "investigator": [
        {
          "first_name": "",
          "middle_name": "",
          "last_name": "",
          "degrees": "",
          "role": "",
          "affiliation": ""
        }
      ]
    }
  ],
  "required_header": "         ClinicalTrials.gov processed this data on May 09, 2018Link to the current ClinicalTrials.gov record.https://clinicaltrials.gov/show/NCT03483103         ",
  "id_info": "         017006NCT03483103         ",
  "brief_title": "         Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-NHL-006)         ",
  "official_title": "         A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)         ",
  "sponsors": "         Juno Therapeutics, Inc.IndustryCelgene CorporationIndustry         ",
  "source": "         Juno Therapeutics, Inc.         ",
  "oversight_info": "         YesYesNo         ",
  "brief_summary": "                This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of       lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are       refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma       (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance       status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel       and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status,       quality of life, and survival.              ",
  "overall_status": "         Not yet recruiting         ",
  "start_date": "         May 2, 2018         ",
  "completion_date": "         May 2, 2021         ",
  "primary_completion_date": "         May 2, 2021         ",
  "phase": "         Phase 2         ",
  "study_type": "         Interventional         ",
  "has_expanded_access": "         No         ",
  "study_design_info": "         Single Group AssignmentTreatmentNone (Open Label)         ",
  Antitumor
  activityThrough
  Month
  24Overall
  response
  rate
  (complete
  response
  +
  partial
  response)
  based
  on
  "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification"
  Adverse
  events90
  daysProportion
  of
  subjects
  experiencing
  adverse
  eventsLaboratory
  abnormalities90
  daysProportion
  of
  subjects
  experiencing
  laboratory
  abnormalitiesAntitumor
  activityThrough
  Month
  24Complete
  response
  rate
  based
  on
  "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification"
  Antitumor
  activityThrough
  Month
  24Duration
  of
  responseMaximum
  concentration
  (Cmax)
  of
  lisocabtagene
  maraleucel
  in
  bloodThrough
  Month
  24Maximum
  concentration
  of
  lisocabtagene
  maraleucel
  in
  bloodTime
  of
  the
  maximum
  concentration
  (Tmax)
  of
  lisocabtagene
  maraleucel
  in
  bloodThrough
  Month
  24Time
  of
  the
  maximum
  concentration
  of
  lisocabtagene
  maraleucel
  in
  bloodArea
  under
  the
  curve
  of
  (AUC)
  lisocabtagene
  maraleucel
  concentration
  in
  bloodThrough
  Month
  24Area
  under
  the
  curve
  of
  lisocabtagene
  maraleucel
  in
  bloodProgression-free
  survivalThrough
  Month
  24Progression-free
  survivalOverall
  survivalThrough
  Month
  24Overall
  survivalHealth-related
  quality
  of
  life
  and
  health
  economics
  and
  outcomes
  researchThrough
  Month
  24The
  European
  Organization
  for
  Research
  and
  Treatment
  of
  Cancer
  (EORTC)
  QLQ-C30
  is
  a
  validated
  quality
  of
  life
  measure
  applicable
  to
  subjects
  with
  any
  cancer
  diagnosis.
  It
  is
  composed
  of
  30
  items
  that
  address
  general
  physical
  symptoms,
  physical
  functioning,
  fatigue
  and
  malaise,
  and
  social
  and
  emotional
  functioning.
  Subscale
  scores
  are
  transformed
  to
  a
  0
  to
  100
  scale,
  with
  higher
  scores
  on
  functional
  scales
  indicating
  better
  function
  and
  higher
  scores
  on
  symptom
  scales
  indicating
  worse
  symptoms.
  A
  10
  point
  change
  in
  the
  scoring
  is
  considered
  to
  be
  a
  meaningful
  change
  in
  HRQoL.Health-related
  quality
  of
  life
  and
  health
  economics
  and
  outcomes
  researchThrough
  Month
  24The
  EuroQol-5D
  (EQ-5D)
  is
  a
  standardized
  measure
  of
  health
  status
  developed
  by
  the
  EuroQol
  Group
  in
  order
  to
  provide
  a
  simple,
  generic
  measure
  of
  health
  for
  clinical
  and
  economic
  appraisal.
  The
  EQ-5D-5L
  consists
  of
  the
  EQ-5D-5L
  descriptive
  system
  and
  the
  EQ
  Visual
  Analogue
  scale
  (EQ
  VAS).
  The
  descriptive
  system
  comprises
  dimensions
  (mobility,
  self-care,
  usual
  activities,
  pain/discomfort,
  anxiety/depression).
  Each
  dimension
  has
  5
  levels
  (no
  problems,
  slight
  problems,
  moderate
  problems,
  severe
  problems,
  extreme
  problems).
  The
  VAS
  rating
  scale
  is
  a
  vertical
  20
  cm
  visual
  analogue
  scale
  with
  the
  end
  points
  labeled
  best
  imaginable
  health
  state
  at
  the
  top
  and
  worst
  imaginable
  health
  state
  at
  the
  bottom
  having
  numeric
  values
  of
  100
  and
  0
  respectively.
  The
  participant
  is
  asked
  to
  indicate
  his/her
  health
  state
  by
  ticking
  (or
  placing
  a
  cross)
  in
  the
  box
  against
  the
  most
  appropriate
  statement
  in
  each
  of
  the
  5
  dimensions.Health-related
  quality
  of
  life
  and
  health
  economics
  and
  outcomes
  researchThrough
  Month
  24Numbers
  of
  intensive
  care
  unit
  inpatient
  days
  and
  non-ICU
  inpatient
  days
  and
  reasons
  for
  hospitalization
  "number_of_arms": "         1         ",
  "enrollment": "         56         ",
  Lymphoma,
  Non-HodgkinLymphoma,
  NonhodgkinLymphoma,
  B-CellLymphoma,
  Large
  B-Cell,
  Diffuse
  "arm_group": "         TreatmentExperimentalLisocabtagene maraleucel at a dose of 1×10^8 CAR+ T cells (5×10^7 CD8+ CAR+ T cells and 5×10^7 CD4+ CAR+ T cells), will be given IV in a single-dose schedule on Day 1 (between 2 and 7 days following the completion of lymphodepleting chemotherapy).         ",
  "intervention": "         Biologicallisocabtagene maraleucellisocabtagene maraleucelTreatmentJCAR017liso-cel         ",
  "eligibility": "                  Inclusion Criteria:            -  Confirmation of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma of the              following histology at relapse: diffuse large B-cell lymphoma (DLBCL), not otherwise              specified (NOS; de novo or transformed follicular lymphoma [tFL]), high-grade B-cell              lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology              (double/triple hit lymphoma [DHL/THL]), and follicular lymphoma Grade 3B per WHO 2016              classification            -  Previous treatment must include treatment with a single line of chemoimmunotherapy              containing an anthracycline and a CD20-targeted agent            -  Subjects must be deemed ineligible for both high-dose chemotherapy and hematopoietic              stem cell transplant (based on age, performance status and/or comorbidities) while              also having adequate organ function for CAR T cell treatment.            -  Positron emission tomography (PET)-positive disease            -  Enough tumor material must be available for central confirmation of diagnosis,              otherwise a new tumor biopsy is mandated.            -  ECOG performance status of 0, or 1, or 2            -  Adequate vascular access for leukapheresis procedure (either peripheral line or              surgically-placed line)          Exclusion Criteria:            -  Subjects with central nervous system (CNS)-only involvement by malignancy (note:              subjects with secondary CNS involvement are allowed on study)            -  History of another primary malignancy that has not been in remission for at least 2              years.            -  Previous treatment with CD19-targeted therapy, with the exception of prior              lisocabtagene maraleucel treatment in this protocol for subjects receiving retreatment            -  Active hepatitis B or hepatitis C infection at the time of screening            -  History of or active human immunodeficiency virus (HIV) infection at the time of              screening            -  Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate              antibiotics or other treatment at the time of leukapheresis or lisocabtagene              maraleucel administration            -  History of any one of the following cardiovascular conditions within the past 6              months: Class III or IV heart failure as defined by the New York Heart Association,              cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other              clinically significant cardiac disease            -  History or presence of clinically relevant CNS pathology            -  Nursing women            -  Subject does not meet protocol-specified washout periods for prior treatments            -  Prior hematopoietic stem cell transplant       All18 YearsN/ANo         ",
  "overall_official": "         Nick Trede, MD, PhDStudy DirectorJuno Therapeutics, Inc.         ",
  "overall_contact": "         Juno Medical Information866-599-JUNO (5866)medicalinformation@junotherapeutics.com         ",
  University
  of
  Pittsburgh
  Medical
  Center,
  Hillman
  Cancer
  CenterPittsburghPennsylvania15232United
  StatesNot
  yet
  recruitingLinda
  Fukas,
  RN412-623-6037fukaslj@upmc.eduBridget
  Sweterlitschsweterlitschbm@ph.upmc.eduAlison
  Sehgal,
  MDPrincipal
  Investigator
  "location_countries": "         United States         ",
  "verification_date": "         April 2018         ",
  "study_first_submitted": "         March 23, 2018         ",
  "study_first_submitted_qc": "         March 23, 2018         ",
  "study_first_posted": "         March 30, 2018         ",
  "last_update_submitted": "         April 4, 2018         ",
  "last_update_submitted_qc": "         April 4, 2018         ",
  "last_update_posted": "         April 6, 2018         ",
  "responsible_party": "         Sponsor         ",
  JCAR017
  lisocabtagene
  maraleucel
  NHL
  chimeric
  antigen
  receptor
  CAR
  CAR
  T
  cell
  autologous
  T
  cell
  therapy
  immunotherapy
  cell
  therapy
  liso-cel
  "condition_browse": "         LymphomaLymphoma, Non-HodgkinLymphoma, B-CellLymphoma, Large B-Cell, Diffuse         "
}